glp 1 receptor agonist mechanism of action GLP1 Agonists—Effects beyond Obesity and Diabetes Recent updates on GLP-1 agonists:

Figure 28: Photograph of the gastrointestinal researchers at Bispebjerg Hospital in 1975, credit: Figure 1.3.3, Holst 2024

Multiple sclerosis GLP-1 receptor agonists show neuroprotective properties that extend to autoimmune conditions of the central nervous system

Although the occurrence of EDKA associated with SGLT2 inhibitors is rather rare, several predisposing factors have been recognised

Regional support for healthcare advancements and access to innovative therapies further strengthens North Americas position in the market, making it a major contributor to GLP-1 receptor agonist demand

Over the next several years, as more innovative therapies enter clinical development and commercialization, the GLP-1 field is expected to maintain rapid growth while expanding into broader metabolic disease management

Differentiation in GLP-1 Products *Weight-related comorbidities may include but are not limited to hypertension, dyslipidemia, CVD, sleep apnea, and T2D